The search for novel drug leads for predominately antitumor therapies by utilizing mother nature's pharmacophoric libraries

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 2, 2005, Pages 207-227

  Kingston, David G I ^a   Newman, David J ^b  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Combinatorial scaffolds; Drug discovery; Natural products

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; AK 37; ANTINEOPLASTIC AGENT; BORTEZOMIB; CHAP 31; COMBRETASTATIN; DACINOSTAT; DNA TOPOISOMERASE INHIBITOR; EPOTHILONE DERIVATIVE; EPOXOMICIN; FR 901228; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEXAMETHYLENEBISACETAMIDE; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1 INHIBITOR; IRCINASTATIN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; MANZAMINE A; NATURAL PRODUCT; PACLITAXEL; PEDERIN; PROTEIN KINASE INHIBITOR; TAXANE DERIVATIVE; TRICHOSTATIN A; TUBULIN; TUBULIN INTERACTIVE AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG DESIGN; ENZYME INHIBITION; HUMAN; INHIBITION KINETICS; MEDICINAL PLANT; PHARMACOPHORE; PROTEIN INTERACTION; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL FACTORS; DNA-BINDING PROTEINS; DRUG DESIGN; ENZYME INDUCTION; ENZYME INHIBITORS; GENE LIBRARY; HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NUCLEAR PROTEINS; PROTEIN KINASES; TRANSCRIPTION FACTORS; TUBULIN;

EID: 14844325717     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Kingston DG, Newman DJ: Mother nature's combinatorial libraries; their influence on the synthesis of drugs. Curr Opin Drug Discovery Dev (2002) 5(2):304-316.
2. Peraud O, Mohamed N, Montalvo N, Enticknap JJ, Hill RT, Hamann MT: Novel and diverse assemblage of actinomycetes in marine sponges: A resource for drug discovery. Annual Meeting of the Society for Industrial Microbiology, Anaheim, CA, USA (2004).
3. Kasanah N, Rao KV, Peng JN, Donla M, Peraud O, Anderson M, Hill RT, Hamann MT: The manzamines, progress toward kilogram-scale production and application as a control for malaria. Annual Meeting of the Society for Industrial Microbiology, Anaheim, CA, USA (2004). Provides the first definitive report of a compound isolated from a marine invertebrate that was produced fermentatively from a microbe isolated from the same sponge specimen.
4. Kellner RL: Molecular identification of an endosymbiotic bacterium associated with pederin biosynthesis in Paederus sabaeus (Colsoptera: Staphylinidae). Insect Biochem Mol Biol (2002) 32(4):389-395.
5. Piel J, Hofer I, Hui D: Evidence for a symbiosis island involved in horizontal acquisition of pederin biosynthetic capabilities by the bacterial symbiont of Paederus fuscipes beetles. J Bacteriol (2004) 186(5):1280-1286. Presents the first genetic proof that the active principle of the blister beetle was made by a commensal microbe.
6. Piel J, Hui D, Wen G, Butzke D, Platzer M, Fusetani N, Matsunaga S: Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei. Proc Natl Acad Sci USA (2004) 101(46):16222-16227. Discusses isolation of the genes producing the pederin-like marine metabolite directly from the producing sponge.
7. Pettit GR, Xu JP, Chapuis JC, Pettit RK, Tackett LP, Doubek DL, Hooper JN, Schmidt JM: Antineoplastic agents. 520. Isolation and structure of irciniastatins A and B from the Indo-Pacific marine sponge Ircinia ramosa. J Med Chem (2004) 47(5):1149-1152.
8. Cichewicz RH, Valeriote FA, Crews P: Psymberin, a potent sponge-derived cytotoxin from Psammocinia distantly related to the pederin family. Org Lett (2004) 6(12):1951-1954.
9. Cragg GM, Newman DJ: A tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J Nat Prod (2004) 67(2):232-244.
10. Kondoh M, Usui T, Kobayashi S, Tsuchiya K, Nishikawa K, Nishikiori T, Mayumi T, Osada H: Cell cycle arrest and antitumor activity of pironetin and its derivatives. Cancer Lett (1998) 126(1):29-32.
11. 352 of α-tubulin. Chem Biol (2004) 11(6):799-806. Presents direct evidence for the covalent binding of α-tubulin.
12. Denny WA: Emerging topoisomerase inhibitors as anticancer drugs. Expert Opin Emerg Drugs (2004) 9(1):105-133. Provides good coverage of the current state-of-the-art of topoisomerase inhibitors.
13. Marshall KM, Holden JA, Koller A, Kashman Y, Copp BR, Barrows LR: AK37: The first pyridoacridine described capable of stabilizing the topoisomerase I cleavable complex. Anticancer Drugs (2004) 15(9):907-913.
14. Marshall KM, Barrows LR: Biological activities of pyridoacridines. Nat Prod Rep (2004) 21(6):731-751. An excellent review of the biochemistry of these marine-derived compounds.
15. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ: Selective killing of cancer cells by β-lapachone: Direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA (2003) 100(5):2674-2678.
16. Choi BT, Cheong J, Choi YH: β-Lapachone-induced apoptosis is associated with activation of caspase-3 and inactivation of NF-κB in human colon cancer HCT-116 cells. Anticancer Drugs (2003) 14(10):845-850.
17. Ravelo AG, Estevez-Braun A, Chavez-Orellana H, Perez-Sacau E, Mesa-Siverio D: Recent studies on natural products as anticancer agents. Curr Top Med Chem (2004) 4(2):241-265.
18. Kisselev AF, Goldberg AL: Proteasome inhibitors: From research tools to drug candidates. Chem Biol (2001) 8(8):739-758.
19. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med (2004) 351(18):1860-1873.
20. Newman DJ, Cragg GM, Snader KM: Natural products as sources of new drugs over the period 1981-2002. J Nat Prod (2003) 66(7):1022-1037.
21. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell (2004) 5(5):417-421. Discussion of the development of PS-341 (bortezomib) by its inventor.
22. Brannigan JA, Dodson G, Duggleby HJ, Moody PC, Smith JL, Tomchick DR, Murzin AG: A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature (1995) 378(6555):416-419.
23. Omura S, Fujimoto T, Otoguro K, Matsuzaki K, Moriguchi R, Tanaka H, Sasaki Y: Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot (Tokyo) (1991) 44(1):113-116.
24. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL: Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 268(5211):726-731.
25. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL, Rock KL: Lactacystin and clasto-lactacystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem (1997) 272(20):13437-13445.
26. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL: Mechanistic studies on the inactivation of the proleosome by lactacystin - a central role for clasto-lactacystin β-lactone. J Biol Chem (1996) 271(13):7273-7276.
27. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, Nunes SL, Palombella VJ, Parent LA, Plamodon L, Stein RL: Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem (1997) 272(1):182-188.
28. Corey EJ, Li WD: Total synthesis and biological activity of lactacystin, omuralide and analogs. Chem Pharm Bull (Tokyo) (1999) 47(1):1-10.
29. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W: Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed (2003) 42(3):355-357. A novel proteasome inhibitor produced by fermentation of an obligate marine microbe.
30. Reddy LR, Saravan P, Corey EJ: A simple stereocontrolled synthesis of Salinosporamide A. J Am Chem Soc (2004) 126(20):6230-6231.
31. Corey EJ, Li WZ, Nagamitsu T, Fenteany G: The structural requirements for inhibition of proteasome function by the lactacystin-derived β-lactone and synthetic analogs. Tetrahedron (1999) 55:3305-3316.
32. Soucy F, Grenier L, Behnke ML, Destree AT, McCormack TA, Adams J, Plamodon L: A novel and efficient synthesis of a highly active analogue of clasto-lactacystin β-lactone. J Am Chem Soc (1999) 121(43):9967-9976.
33. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J: Proteasome inhibition: A novel mechanism to combat asthma. J Allergy Clin Immunol (1999) 104(2 Pt 1):294-300.
34. Campbell B, Adams J, Shin YK, Lefer AM: Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol (1999) 31(2):467-476.
35. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC: Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat modal of focal cerebral ischemia. Stroke (2000) 31(7):1686-1693.
36. Williams AJ, Hale SL, Moffett JR, Dave JR, Elliott PJ, Adams J, Tortella FC: Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-κB activation, gliosls and leukocyte infiltration. J Cereb Blood Flow Metab (2003) 23(1):75-87.
37. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA (1999) 96(18):10403-10408.
38. Meng L, Kwok BH, Sin N, Crews CM: Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res (1999) 59(12):2798-2801.
39. Groll M, Kim KB, Kairies N, Huber R, Crews CM: Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of α',β'-epoxyketone proteasome inhibitors. J Am Chem Soc (2000) 122:1237-1238. Presents direct evidence for the mechanism of action of the epoxy-containing inhibitors.
40. Koguchi Y, Kohno J, Nishio M, Takahashi K, Okuda T, Ohnuki T, Komatsubara S: TMC-95A, B, C and D, novel proteasome inhibitors produced by Apiospora montegnai Sacc. TC 1093. Taxonomy, production, isolation and biological activities. J Antibiot (2000) 53(2):105-109.
41. Groll M, Koguchi Y, Huber R, Kohno J: Crystal structure of the 20S proteasome: TMC-95A complex: A non-covalent proteasome inhibitor. J Mol Biol (2001) 311(3):543-548.
42. Nam S, Smith DM, Dou QP: Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem (2001) 276(16):13322-13330.
43. Johnstone RW: Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Disc (2002) 1(4):287-299. Provides an excellent review of the field of HDAC inhibitors.
44. Kristeleit R, Stimson L, Workman P, Aheme W: Histone modification enzymes: Novel targets for cancer drugs. Expert Opin Emerg Drugs (2004)9(1):135-154.
45. De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB: Histone deacetylases: Characterization of the classical HDAC family. Biochem J (2003) 370(Pt 3):737-749.
46. Sears R, Ohtani K, Nevins JR: Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol (1997) 17(9):5227-5235.
47. Dang CV: c-Myc target genes involved in cell growth, apoptosis and metabolism. Mol Cell Biol (1999) 19(1):1-11.
48. Nomura T, Khan MM, Kaul SC, Dong HD, Wadhwa R, Colmenares C, Kohno I, Ishii S: Ski is a component of the histone deacetylase complex required for franscriptional repression by Mad and thyroid hormone receptor. Genes Dev (1999) 13(4):412-423.
49. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A: Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature (1998) 391(6667):601-605.
50. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T: Retinoblatoma protein recruits histone deacetylase to repress transcription. Nature (1998) 391(6667):597-601.
51. Cress WD, Seto E: Histone deacetylases, transcriptional control and cancer. J Cell Physiol (2000) 184(1):1-16.
52. Sellers WR, Kaelin WG Jr: Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol (1997) 15(11):3301-3312.
53. Fischle W, Kiermer V, Dequiedt F, Verdin E: The emerging role of class II histone deacetylases. Biochem Cell Biol (2001) 79(3):337-348.
54. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW et al: Histone deacetylases induce angiogenesis by negative regulation of tumour suppressor genes. Nat Med (2001) 7(4):437-443.
55. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V: Histone deacetylase inhibitors as antiangiogenic agents altering vascular endothelial growth factor signalling. Oncogene (2002) 21(3):427-436.
56. Remiszewski SW: Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr Opin Drug Discovery Dev (2002) 5(4):487-499.
57. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S: Histone deacetylase as a new target of cancer chemotherapy. Cancer Chemother Pharmacol (2001) 48(Suppl 1):S20-S26.
58. Yoshida M, Matsuyama A, Komatsu Y, Nishino N: From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem (2003) 10(22):2351-2358.
59. Tsuji N, Kobayashi N, Nagashima K, Wakisaka Y, Koizumi K: A new antifungal antibiotic, trichostatin. J Antibiot (1976) 29(1):1-6.
60. Vanhaecke T, Papeleu P, Elaut G, Rogiers V: Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: Toxicological point of view. Curr Med Chem (2004) 11(12):1629-1643.
61. Van Lint C, Emiliani S, Verdin E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr (1996) 5(4-5):245-253.
62. Mariadason JM, Comer GA, Augenlicht LH: Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: Comparison with trichostatin A, sulindac and curcumin and implications for prevention of colon cancer. Cancer Res (2000) 60(16):4561-4572.
63. Brinkmann H, Dahler AL, Popa C, Sereweko MM, Parsons PG, Gabrielli BG, Burgess AJ, Saunders NA: Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem (2001) 276(25):22491-22499.
64. Andreeff M, Stone R, Michaeli J, Young CW, Tong W, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA: Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia - a phase II clinical trial with a differentiation-inducing agent. Blood (1992) 80(10):2604-2609.
65. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M et al: Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 9(10 Pt 1):3578-3588.
66. Secrist JP, Zhou X, Richon VM: HDAC inhibitors for the treatment of cancer. Curr Opin Invest Drugs (2003) 4(12):1422-1427. Discusses the clinical aspects of HDAC inhibitors.
67. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer(2001) 1(3):194-202.
68. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R et al: Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res (2001) 7(4):962-970.
69. Jung M, Brosch G, Kolle D, Scherf H, Gerhauser C, Loidl P: Amide analogues of frichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem (1999) 42(22):4669-4679.
70. Remiszewski SW, Sambucetti LC, Atadja P, Bair KW, Cornell WD, Green MA, Howell KL, Jung M, Kwon P, Trogani N, Walker H: Inhibitors of human histone deacetylases: Synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem (2002) 45(4):753-757.
71. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T: Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem (1993) 268(30):22429-22435.
72. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D: Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem (1999) 274(49):34940-34947.
73. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S: Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptides including trapoxin. Proc Natl Acad Sci USA (2001) 98(1):87-92.
74. Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S et al: Cyclic hydroxamic acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res (2001) 61(11):4459-4466.
75. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No 968. III. antitumor activities on experimental tumors in mice. J Antibiot (1994) 47(3):315-323.
76. 1 arrest with downregulation of cyclin D1 with upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer (2000) 83(6):817-825.
77. Arabshahi L, Schmitz FJ: Brominated tyrosine metabolites from an unidentified sponge. J Org Chem (1987) 52:3584-3586.
78. Quinoa E, Crews P: Phenolic constituents of Psammaplysilla. Tetrahedron Lett (1987) 28(28):3229-3232.
79. Pina IC, Gautschi JT, Wang GY, Sanders ML, Schmitz FJ, France D, Cornell-Kennon S, Sarabucetti LC, Remiszewski SW, Perez LB, Bair KW et al: Psammaplins from the sponge Pseudoceritina purpurea: Inhibition of both histone deacetylase and DMA methyltransferase. J Org Chem (2003) 68(10):3866-3873.
80. Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G et al: N-Hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2E)-N-hydroxy-3-[4- [[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem (2003) 46(21):4609-4624.
81. Remiszewski SW: The discovery of NVP-LAQ824: From concept to clinic. Curr Med Chem (2003) 10(22):2393-2402. Describes the genesis and ultimate synthesis of this compound, based upon three natural product inhibitors.
82. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski SW, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC et al: NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood (2003) 102(7):2615-2622.
83. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ: A high affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 425(6956):407-410.
84. Lee YS, Marcu MG, Neckers L: Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes transcis isomerization of geldanamycin. Chem Biol(2004) 11(7):991-998.
85. Jez JM, Chen JC, Rastelli G, Stroud RM, Santi DV: Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. Chem Biol (2003) 10(4):361-368.
86. Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S et al: Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. J Med Chem (2004) 47(15):3865-3873.
87. Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, Myles DC: Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem (2004) 12(20):5317-5329.
88. Snader KM et al: 17-Dimethylaminoethylamino-17-desmethoxy-geldanamycin (17-DMAG), a potent Hsp90 inhibitor with improved pharmaceutical and antitumor properties. Signal Transduction Modulators in Cancer Therapy - First International Symposium, Amsterdam, the Netherlands (2002):Abs P044.
89. Snader KM: Benzoquinone ansamycins. In: Anticancer Agents from Natural Sources, Cragg GM, Kingston DGI, Newman DJ (Eds), CRC Press/Taylor and Francis, Boca Raton, FL, USA (2005): in press.
90. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N: A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes HER2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol (2001) 8(3):289-299.
91. Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N: Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets (2003) 3(5):371-376.
92. Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N: Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of HER2 tyrosine kinase. Bioorg Med Chem (2002) 10(11):3555-3564.
93. Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G: Targeting wide-range oncogenic transformation via PU24FCI, a specific inhibitor of tumor Hsp90. Chem Biol (2004) 11(6):787-797. A 'tour-de-force' providing examples of drug discovery using chemical intuition rather than in silico modeling.
94. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L: 17AAG: Low target binding affinity and potent cell activity - finding an explanation. Mol Cancer Ther (2003) 2(2):123-129.
95. Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, Drysdale M, Collier A, Massey M, Davies N, Fink A et al: Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms. Chem Biol (2004) 11(6):775-785.
96. Meijer L, Raymond E: Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res (2003) 36(6):417-425. Describes the evolution of the purine-based CDK inhibitors.
97. Parker CW, Entsch B, Letham DS: Inhibitors of two enzymes which metabolize cytokinins. Phytochemistry (1986) 25:303-310.
98. Chang YT, Gray NS, Rosania GR, Sutherlin DP, Kwon S, Norman TC, Sarohia R, Leost M, Meijer L, Schultz PG: Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem Biol (1999) 6(6):361-375.
99. Maugard T, Enaud E, Choisy P, Legoy MD: Identification of an indigo precursor from leaves of Isatis tinctoria (Woad). Phytochemistry (2001) 58(6):897-904.
100. Cooksey CJ: Tyrian purple: 6,6′-Dibromoindigo and related compounds. Molecules (2001) 6:736-769.
101. MacNeil IA, Tiong CL, Minor C, August PR, Grossman TH, Loiacono KA, Lynch BA, Phillips T, Narula S, Sundaramoorthi R, Tyler A et al: Expression and isolation of antimicrobial small molecules from soil DNA libraries. J Mol Microbiol Biotechnol (2001) 3(2):301-308.
102. Adachi J, Mori Y, Matsui S, Takigam H, Fujino J, Kitagawa H, Miller CA III, Kato T, Saeki K, Matsuda T: Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem (2001) 276(34):31475-31478.
103. Chen DH, Xie JX: Chemical constituents of a traditional Chinese medicine Ging Dai. Zhongcaoyao (1984) 15:6-8.
104. Xiao Z, Hao Y, Liu B, Qian L: Indirubin and mesoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma (2002) 43(9):1763-1768.
105. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, Crovace C et al: GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol (2003) 10(12):1255-1266. An excellent review of the research involved in the discovery of the multiple activities of simple indirubins and their derivatives.
106. Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe SM, Pearl L, Leost M, Greengard P et al: Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem (2004) 47(4):935-946.
107. Guengerich FP, Sorrells JL, Schmitt S, Krauser JA, Aryal P, Meijer L: Generation of new protein kinase inhibitors utilizing cytochrome P450 mutant enzymes for indigoid synthesis. J Med Chem (2004) 47(12):3236-3241. Provides evidence that cytochrome P450s can be expressed in surrogate hosts and can convert indoles to indirubins.
108. Li QS, Schwaneberg U, Fischer P, Schmid RD: Directed evolution of the fatty-acid hydroxylase P450 BM-3 into an indole-hydroxylating catalyst. Chemistry (2000) 6(9):1531-1536.
109. Gillam EM, Notley LM, Cai H, DeVoss JJ, Guengerich FP: Oxidation of indole by cytochrome P450 enzymes. Biochemistry (2000) 39(45):13817-13824.
110. Knockaert M, Blondel M, Bach S, Leost M, Elbi C, Hager GL, Nagy SR, Han D, Denison M, Ffrenoh M, Meijer L et al: Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediates the antiproliferative effects of indirubins. Oncogene (2004) 23(25):4400-4412.
111. Denison MS, Nagy SR: Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol (2003) 43:309-334.
112. Cohen P, Goedert M: GSK3 inhibitors: Development and therapeutic potential. Nat Rev Drug Disc (2004) 3(6):479-487. A thorough review of the roles of GSK-3 kinase in biology.
113. Gompel M, Leost M, De Kier Joffe EB, Puricelli L, Franco LH, Palermo J, Meijer L: Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. Bioorg Med Chem Lett (2004) 14(7):1703-1707.
114. Fischer PM: The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr Med Chem (2004) 11(12):1563-1583. A thorough review of the design of protein kinase inhibitors by one of the leading medicinal chemists in the field.
115. Breinbauer R, Vetter IR, Waldmann H: From protein domains to drug candidates - natural products as guiding principles in compound library design and synthesis of compound libraries. Angew Chem Int Ed (2002) 41(16):2878-2890. Describes how to devise new inhibitors from older natural products by utilizing topological information from proteins.
116. Brohm D, Metzger S, Bhargava A, Muller O, Lieb F, Waldmann H: Natural products are biologically validated starting points in structural space for compound library development: Solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. Angew Chem Int Ed (2002) 41(2):307-311.
117. Koonin EV, Wolf YI, Karev GP: The structure of the protein universe and genome evolution. Nature (2002) 420(6912):218-223.
118. Evans BE, Riffle KE, Bock MG, DiPardo RM, Fredinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS, Chang RSL, Lotti VJ et al: Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem (1988) 31(12):2235-2246.
119. Nicolaou KC, Pfefferkorn JA, Roecker AJ, Cao G-Q, Barluenga S, Mitchell HJ: Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J Am Chem Soc (2000) 122(41):9939-9953.
120. Nicolaou KC, Pfefferkorn JA, Mitchell HJ, Roecker AJ, Barluenga S, Cao GQ, Affleck RL, Lillig JE: Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using nanokans and optical encoding. J Am Chem Soc (2000) 122(41):9954-9967.
121. Nicolaou KC, Pfefferkorn JA, Barluenga S, Mitchell HJ, Roecker AJ, Cao GQ: Natural product-like combinatorial libraries based on privileged structures. 3. The 'libraries from libraries' principle for diversity enhancement of benzopyran libraries. J Am Chem Soc (2000) 122(41):9968-9976.
122. Kobayashi J, Madono T, Shigemori H: Nakijiquinones C and D, new sesquiterpenoid quinones with a hydroxy amino acid residue from a marine sponge inhibiting c-Erb2 kinase. Tetrahedron (1995) 51(40):10867-10974.
123. Zhou BN, Johnson RK, Mattern MR, Fisher PW, Kingston DG: The first naturally occurring Tie2 kinase inhibitor. Org Lett (2001) 3(25):4047-4049.
124. Arnold LD, Calderwood DJ. Dixon RW, Johnston DN, Kamens JS, Munschauer R, Rafferty P, Ratnofsky SE: Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective Inhibitors of lck-I. Bioorg Med Chem Lett (2000) 10(19):2167-2170.
125. Burchat AF, Calderwood DJ, Hirst GC, Holman NJ. Johnston DN, Munschauer R, Rafferty P, Tometzki GB: Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck-II. Bioorg Med Chem Lett (2000) 10(19):2171-2174.
126. Calderwood DJ, Johnston DN, Munschauer R, Rafferty P: Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of lck. Bioorg Med Chem Lett (2002) 12(12):1683-1686.
127. Burchat AF, Calderwood DJ, Friedman MM, Hirst GC, Li B, Rafferty P, Ritter K, Skinner BS: Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of lck - a selective insight. Bioorg Med Chem Lett (2002) 12(12):1687-1690.
128. Kissau L, Stahl P, Mazitschek R, Giannis A, Waldmann H: Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. J Med Chem (2003) 48(14):2917-2931.
129. Koch MA, Breinbauer R, Waldmann H: Protein structure similarity as guiding principle for combinatorial library design. Biol Chem (2003) 384(9):1265-1272. Describes research with 'protein-directed' syntheses.
130. 4 hydrolase. Bioorg Med Chem (1995) 3(7):969-995.
131. 4 hydrolase: A new target for antiinflammatory intervention. Curr Med Chem (1997) 4(1):67-78.
132. Chang YT, Choi S, Bae YS, Burdett M, Moon HS, Lee JW, Gray NS, Schultz PG, Meijer L, Chung SK, Choi KY et al: Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. ChemBioChem (2002)3(9):897-901.
133. Armstrong JI, Portley AR, Chang YT, Nierengarten DM, Cook BN, Bowman KG, Bishop A, Gray NS, Shokat KM, Schultz PG, Bertozzi CR: Discovery of carbohydrate sulfotransferase inhibitors from a kinase-directed library. Angew Chem Int Ed (2000) 39(7):1303-1306.
134. Verdugo DE, Cancilla MT, Ge X, Gray NS, Chang YT, Schultz PG, Negishi M, Leary JA, Bertozzi CR: Discovery of estrogen sulfotransferase inhibitors from a purine library screen. J Med Chem (2001) 44(17):2683-2686.
135. Chapman E, Ding S, Schultz PG, Wong CH: A potent and highly selective sulfotransferase inhibitor. J Am Chem Soc (2002) 124(49):14524-14525.
136. Giaccia A, Siim BG, Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Disc (2003) 2(10):803-811.
137. Kunkel MW, Kirkpatrick DL, Johnson JI, Powis G: Cell-line directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. Anticancer Drug Des (1997) 12(8):659-670.
138. 1. J Pharmacol Exp Ther (2001) 296(2):364-371.
139. Wipf P, Hopkins TD, Jung J-K, Rodriguez S, Birmingham A, Southwick EC, Lazo JS, Powis G: New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead. Bioorg Med Chem Letts (2001) 11(19)2637-2641.
140. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G: The thioredoxin redox inhibitors 1-methylpropyl 2-imidazoyl disulfide and pleurotin inhibit hypoxia-induced factor 1-α and vascular endothelial growth factor formation. Mol Cancer Ther (2003) 2(3):235-243.
141. Wipf P, Lynch SM, Birmingham A, Tamayo G, Jimenez A, Campos N, Powis G: Natural product based inhibitors of the thioredoxin-thioredoxin reductase system. Org Biomol Chem (2004) 2(11):1651-1658. Discusses the further utilization of natural products to develop an existing structure-function relationship.
142. Borman S: Rescuing combichem. Chem Eng News (2004) 82(40):32-40. 'Classical' combinatorial chemists begin to recognize the value of natural product scaffolds.
143. Ganesan A: Natural products as a hunting ground for combinatorial chemistry. Curr Opin Biotech (2004) 15(6):584-590.
144. Ortholand JY, Ganesan A: Natural products and combinatorial chemistry: Back to the future. Curr Opin Chem Biol (2004) 8(3):271-280.
145. Boldi AM: Libraries from natural product-like scaffolds. Curr Opin Chem Biol (2004) 8(3):281-286. Covers the role of natural product scaffolds.
146. Gronemeyer H, Gustaffson JA, Laudet V: Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Disc (2004) 3(11):950-964.
147. Alberghina L, Chiaradonna F, Vanoni M: Systems biology and the molecular circuits of cancer. ChemBioChem (2004) 5(10):1322-1333.
148. Meijer L: Le cycle de division cellulaire et sa regulation. Oncologie (2003) 5:311-326. Provides superb cell cycle figures.
149. Andrus MB, Meredith EL, Simmons BL, Sekhar BB, Hicken EJ: Total synthesis of (+)-geldanamycin and (-)-o-quinogeldanamycin with use of asymmetric anti- and syn-glycolate aldol reactions. Org Lett (2002) 4(20):3549-3552.
150. Buckingham J: Dictionary of Natural Products on CD-ROM, Chapman & Hall/CRC Press UK, London, UK (2004).
151. Panek JS, Xu F, Rondon AC: Chiral crotylsilane-based approach to benzoquinoid ansamycins: Total synthesis of (+)-macbecin I. J Am Chem Soc (1998) 120(17):4113-4122.
152. Baker R, Castro J: Total synthesis of (+)-macbecin I. J Chem Soc Perkin Trans I (1990):47-65.
153. Martin SF, Dodge JA, Burgess LE, Limberakis C, Hartmann M: Novel approach to the ansamycin antibiotics macbecin I and herbimycin A. A formal total synthesis of (+)-macbecin I. Tetrahedron (1996) 52(9):3229-3246.